Celcuity Stock Surges As Gedatolisib Data Ignites Wall Street

Celcuity Inc. stocks have been trading up by 8.23 percent after promising clinical trial news boosted investor optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CELC

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Phase 3 VIKTORIA-1 trial showed gedatolisib-based regimens beat alpelisib plus fulvestrant with statistically significant, clinically meaningful progression-free survival and a generally well-tolerated safety profile.
The company plans a supplemental NDA to the FDA and other regulators, while gedatolisib already has Priority Review in another setting with a 2026/07/17 PDUFA date.
Multiple firms lifted CELC price targets into roughly the $150–$189 range and reiterated Buy/Outperform stances, with H.C. Wainwright upgrading to Buy.
Analysts, including Guggenheim, see potential for gedatolisib to expand its eligible patient population by about 50%, pointing to broad second-line HR+/HER2- breast cancer use.
CELC shares recently jumped about 16–17%, trading near $147, as traders quickly repriced the stock on the VIKTORIA-1 news.

Live Update At 16:03:18 EDT: On Thursday, May 14, 2026 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 8.23%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

For traders, CELC is behaving like a classic biotech momentum name: weak fundamentals today, big optionality tomorrow. Celcuity Inc. posted a net loss of about $50.97M for the 2025 quarter, with negative EPS of $0.97 and heavy research and development spending near $37.64M. That is typical for a clinical-stage oncology name leaning hard into its lead asset.

Despite the losses, CELC’s balance sheet looks built for a long runway. Celcuity reported around $165.7M in cash and roughly $441.5M when you include short-term investments, matched against total liabilities of about $366M. Current and quick ratios around 10 show CELC is highly liquid, which traders like in a high-burn story.

More Breaking News

On the tape, CELC has been grinding higher after its spike. The daily chart shows the stock closing at $134.72 after trading as high as $138, well above late-April closes near $120. Intraday, the 5‑minute action shows tight consolidation between roughly $132 and $136, with higher lows through the afternoon. For active traders, CELC now trades like a liquid, institutionally watched biotech with a clear catalyst path.

Why Traders Are Watching CELC Now

CELC has gone from niche biotech to front-page momentum play thanks to its VIKTORIA-1 data. Celcuity reported that the Phase 3 trial in PIK3CA‑mutant HR+/HER2‑ metastatic breast cancer met its primary endpoint. Gedatolisib plus fulvestrant, with or without palbociclib, delivered statistically significant and clinically meaningful progression-free survival gains over alpelisib plus fulvestrant. For oncology traders, that “beats standard of care” language is what re-rates a stock.

Celcuity is not just talking about good numbers; it is acting on them. CELC plans to file a supplemental NDA with the FDA and other regulators off VIKTORIA‑1. Separate topline data cited for the PIK3CA‑mutant cohort, combined with previously positive wild-type results, support broad second-line use of gedatolisib in HR+/HER2‑ advanced breast cancer. On top of that, gedatolisib already carries Priority Review in the PIK3CA wild-type setting, with a PDUFA date set for 2026/07/17. That gives traders a clear regulatory calendar.

Wall Street is piling on. Craig‑Hallum boosted its CELC price target to $189 and reiterated a Buy stance after seeing strong triplet and doublet regimen data. Needham raised its target to $157, while Guggenheim moved to $165, modeling a possible ~50% expansion in the eligible patient pool if a supplemental approval lands. Stifel lifted its target to $150 and now assumes a faster launch and higher U.S. peak sales. Citizens went to $160, citing strong efficacy across regimens. H.C. Wainwright not only hiked its target to $165 but also upgraded CELC to Buy, calling gedatolisib potentially game‑changing and flagging Celcuity as a possible acquisition target.

The result: CELC ripped roughly 16–17%, trading around $147 in early action after the news, and has since held most of those gains. For momentum traders, that combination of major Phase 3 win, imminent regulatory moves, and clustered analyst upgrades makes Celcuity one of the cleanest biotech story trades on the screen.

Conclusion

CELC now sits at the crossroads of clinical success and market speculation. Celcuity’s Phase 3 VIKTORIA‑1 win in PIK3CA‑mutant disease, on top of earlier wild-type data, gives gedatolisib a credible path toward broad second-line HR+/HER2‑ use. The planned supplemental NDA and the already scheduled 2026/07/17 PDUFA date in the Priority Review setting give traders real dates to anchor their trading plans around.

Analyst reaction to CELC has been unusually aligned. Craig‑Hallum, Needham, Guggenheim, Stifel, Citizens, and H.C. Wainwright all raised targets, clustering between about $150 and $189, even after CELC spiked into the $140s. Guggenheim’s estimate of a roughly 50% bigger eligible population if supplemental approval lands helps explain why models are being re‑written in real time. H.C. Wainwright’s upgrade and discussion of Celcuity as a potential acquisition target add another layer of speculative fuel.

For short-term traders, CELC is now a pure “trade the catalysts” story: data at ASCO, regulatory filings, and the PDUFA date. For longer‑term swing traders, it is about whether gedatolisib grows into the role analysts are sketching out. As Tim Sykes likes to say, “The market rewards preparation, not hope.” In a similar vein, disciplined day and swing traders often echo the mindset captured by As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.”. With CELC, that means studying the chart, knowing the calendar, and having a clear trading plan before the next headline hits. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!